Drug – bio-affecting and body treating compositions – In vivo diagnostic or in vivo test agent which contains an...
Reexamination Certificate
2007-04-17
2007-04-17
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
In vivo diagnostic or in vivo test agent which contains an...
C424S093200, C424S204100, C424S205100, C424S211100, C435S235100, C435S236000, C435S239000, C536S023700, C536S023720
Reexamination Certificate
active
10975060
ABSTRACT:
The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.
REFERENCES:
patent: 5166057 (1992-11-01), Palese et al.
patent: 5843451 (1998-12-01), Compans et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6060308 (2000-05-01), Parrington
patent: 6168943 (2001-01-01), Rose
patent: 6376171 (2002-04-01), Hardy et al.
patent: 0 440 219 (1991-08-01), None
patent: 94202089.2 (1994-07-01), None
patent: 0 780 475 (1999-06-01), None
patent: WO 91/03552 (1991-03-01), None
patent: WO 93/06218 (1993-04-01), None
patent: WO 95/08634 (1995-03-01), None
patent: WO 96/10632 (1996-04-01), None
patent: WO 96/40945 (1996-12-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02179 (1998-01-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/50405 (1998-11-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 99/57284 (1999-11-01), None
patent: WO 99/63064 (1999-12-01), None
patent: WO 00/18929 (2000-04-01), None
patent: WO 00/53786 (2000-09-01), None
Hardy et al., “The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function,” Journal of Virology, vol. 74 No. 13, pp. 5880-5885 (Jul. 2000).
Tang et al., “Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viability,” Journal of Virology, vol. 75, No. 23, pp. 11328-11335 (Dec. 2001).
Howorka and Bayley, 1998, Improved protocol for high throughput cysteine scanning mutagenesis. BioTechniques. 25(5):764 6, 768, 770 passim.
Teng and Collins, 1998, Identification of the respiratory syncytial proteins required for formation and passage of helper dependent infectious particles. J Virol. 72(7):5707 16.
Bukreyev et al. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol. Oct. 1996;70(10):6634 41.
Firestone et al. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold passaged (cp) temperature sensitive (ts) cpts 248/404 live attenuated virus vaccine candidate. Virology. Nov. 15, 1996(2):419 22.
Murphy et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. Apr. 1994;32(1):13 36. Review.
Tolley et al. Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine. Dec. 1996;14(17 18):1637 46.
Whitehead et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates, J Virol. Dec. 1999; 73(12):9773 80.
Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. Jul. 1998;11(3):430-439.
Crowe et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. Jul. 1994;12(9):783-790.
Prince et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol. Nov. 2000;74(22):10287-10292.
Tang et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′proximal genome positions of bovine/human parainfluenze virus type 3 on virus replication and immunogenicity. J Virol. Oct. 2003;77(20):10819-10828.
Baer et al., 1990, Virology, 2nd ed., Fields et al., eds., Raven Press Ltd., New York, pp. 883, 887.
Ballart (Eschle) et al., 1991, “Retraction: Infectious measles virus from cloned cDNA,” EMBO J. 10(11):3558.
Ballart et al., 1990, “Infectious measles virus from cloned cDNA,” EMBO J. 9(2):379-384.
Belshe et al., 1992, “Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children,” J. Clin. Microbiol. 30(8):2064-2070.
Calain et al., 1993, “The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA,” J. Virol. 67(8):4822-4830.
Calain et al., 1992, “Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA,” Virol. 191:62-71.
Crowe et al., 1996, “Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene,” Virus Genes 13(3):269-273.
Deng et al., 1991, “High-efficiency protein sythesis from T7 RNA polymerase transcripts in 3T3 fibroblasts,” Gene 109(2):193-201.
Dimcock et al., 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3,” J. Virol. 67(5):2772-2778.
Eilory-Stein et al., 1990, “Cytoplasmic expression system based on constitutive sythesis of bacteriophage T7 RNA polymerase in mammalian cells, ” Proc. Natl. Acad. Sci. USA 87(17):6743-6747.
Fileds et al., 1996, Virology 106, 168.
Fuerst et al., 1986, “Eukaryotic transient-expression system based on recombinant vaccinia virus that sythesizes bacteriophage T7 RNA polymerase,” Proc. Natl. Acad. Sci. USA 83(21):8122-8126.
Gallione et al., 1985, “A single amino acid substitution in a hydrophobic domain causes temperature-sensitive cell-surface transport of a mutant viral glycoprotein,” J. Virol. 54(2):374-382.
Garcin et al., 1995, “A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus,” EMBO J. 14(24):6087-6094.
Kingsbury, ed., 1991, “Deletion mutants of paramyxoviruses,” in: The Paramyxoviruses, Plenum Press, New York, pp. 275-298.
Kolakofsky et al., 1998, Paramyxovirus RNA synthesis and the requirement for hexamer genome length: The Rule of Six revisited, J. Virol . . . 72(2):891-899.
Kucera et al., 1985, “Pathways of the early propagation of virulent and avirulent rabies strains from the eye to the brain,” J. Virol. 55(1):158-162.
Lafay et al., 1994, “Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern,” Vaccine 12(4):317-320.
Li et al., 1988, “Site-specific mutations in vectors that express antigenic and temperature-sensitive pheontypes of the M gene of vesicular stomatitis virus,” J. Virol. 62(10):3729-3737.
Lieber et al., 1989, “High level gene expression in mammalian cells by a nuclear T7-phase RNA polymerase,” Nucleic Acids Res. 17(21):8485-8493.
Ligas et al., 1988, “A herpes simplex virus mutant in which glycoprotein D sequences are replaced by b-galastosidase sequences binds to but is unable to penetrate into cells,” J. Virol. 62(5):1486-1494.
Morita et al., 1987, “Phenotypic revertants of temperature-sensitive M protein mutants of vesicular stomatitis virus: sequence analysis and functional characterization,” J. Virol. 61(2):256-263.
Owens et al., 1993, “Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus,” J. Virol. 67(1):360-365.
Pattnaik, 1992, “Infectious detective interfering particles of VSV from transcripts of a cDNA clone,” Cell 69:1011-1020.
Radecke et al., 1997, “Reverse Genetics Meets the Nonsegmented Negati
Bryant Martin
Jin Hong
Li Shengqiang
Tang Roderick
Campell Bruce R.
Lucas Zachariah
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc.
LandOfFree
Recombinant RSV virus expression systems and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant RSV virus expression systems and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant RSV virus expression systems and vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757409